BC Extra | Dec 17, 2019
Company News

Dec. 16 Company Quick Takes: Greenlight for Roche-Spark deal; plus BMS, Gilead, BioMarin, FDA guidance

Roche cleared to complete Spark takeover  The planned merger of Roche (SIX:ROG; OTCQX:RHHBY) and Spark Therapeutics Inc. (NASDAQ:ONCE) has at last been cleared by the U.S. Federal Trade Commission and U.K. Competition and Markets Authority....
BC Innovations | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory...
BC Extra | Jun 11, 2019
Clinical News

CymaBay down on Phase IIb NASH miss

CymaBay fell $5.04 (45%) to $6.05 on Tuesday after the company announced seladelpar missed the primary endpoint in a Phase IIb trial to treat NASH. In 181 patients with biopsy-confirmed NASH, CymaBay Therapeutics Inc. (NASDAQ:CBAY)...
BC Extra | Apr 25, 2019
Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
BC Extra | Apr 12, 2019
Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...
BC Extra | Apr 11, 2019
Clinical News

Gilead’s NASH combo data suggest benefit, safety

Phase II combination data presented by Gilead at EASL could begin to lay the groundwork for what MOAs will be essential parts of combinations in non-alcoholic steatohepatitis. In a Phase II proof-of-concept trial in 20...
BC Week In Review | Feb 15, 2019
Clinical News

Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis

Gilead Sciences Inc. (NASDAQ:GILD) said selonsertib (GS-4997) missed the primary endpoint in the Phase III STELLAR-4 trial to treat compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Selonsertib is an oral small molecule ASK1 inhibitor. The...
BC Extra | Feb 12, 2019
Clinical News

Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis

Gilead Sciences Inc. (NASDAQ:GILD) said selonsertib (GS-4997) missed the primary endpoint in the Phase III STELLAR-4 trial to treat compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Selonsertib is an oral small molecule ASK1 inhibitor. The...
BC Week In Review | Jan 11, 2019
Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
BC Extra | Jan 7, 2019
Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
Items per page:
1 - 10 of 25